Daniel Landi
Duke University · Duke Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Landi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:04 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05734560 · D2C7-IT and 2141-V11 in Newly Diagnosed GBM PatientsDarell Bigner · recruiting · Newly Diagnosed MGMT Unmethylated Glioblastoma · principal investigator
- Ph2NCT05096481 · PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaNationwide Children's Hospital · recruiting · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma · study chair
- Ph1NCT03615404 · Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent MedulloblastomaGary Archer Ph.D. · completed · Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent · principal investigator
- Ph1NCT03299309 · PEP-CMV in Recurrent MEdulloblastoma/Malignant GliomaDaniel Landi · active not recruiting · Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma · principal investigator
- Ph1NCT03283631 · Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBMGary Archer Ph.D. · terminated · Recurrent Glioblastoma, Recurrent Gliosarcoma · principal investigator
- Ph1NCT03043391 · Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in ChildrenIstari Oncology, Inc. · completed · Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma · principal investigator
- Ph1NCT02664363 · EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant GliomaDaniel Landi · terminated · Glioblastoma, Gliosarcoma · principal investigator
- Ph1NCT01491893 · PVSRIPO for Recurrent Glioblastoma (GBM)Istari Oncology, Inc. · completed · GBM, Glioblastoma, Glioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastomaR01FD007283 · FDA · DUKE UNIVERSITY · fiscal years 2021 to 2025 · $358,401 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP50CA190991 · NCI · DUKE UNIVERSITY · PI David M. Ashley · fiscal years 2014 to 2023Named on NCT03283631
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in diffuse midline glioma (dipg).